Anti-Human HER-2 (Trastuzumab) Fc Muted
|Amount :||500 µg|
|Isotype :||Human IgG1|
|Purification :||>=95% monomer by analytical SEC|
|Content :||Concentration : >= 5.0 mg/ml
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
|Storage condition :||Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.|
|Alternative Name :||ErbB-2, NEU, NGL, HER2, TKR1, CD340, MLN 19, HER-2/neu|
|Immunogen Information :||Human epidermoid carcinoma cells (A431) over-expressing EGFR.|
Expression Host : HEK-293
Pathogen Testing : To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Trastuzumab. Clone 4D5-8 recognizes human erbB-2. This product is for research use only.
Trastuzumab is a monoclonal antibody targeting HER2, a 185 kDa transmembrane glycoprotein that contains an extracellular domain and intracellular tyrosine kinase activity. When it is functioning normally, the HER2 pathway supports cell growth and division. On the other hand, the over expression of HER2 propels cell growth beyond its typical range. This overexpression is associated with some cancers, namely breast and stomach, in which the HER2 protein can be expressed up to 100 times more than in typical cells. Trastuzumab induces an immune-mediated response that triggers the internalization and downregulation of HER2 making it an excellent target for immunotherapy. Several clinical studies are under way which show that anti-HER-2/neu antibodies inhibit the growth and proliferation of these tumor cells In vitro as well as In vivo.
Endotoxin : <= 1.0 EU/mg as determined by the LAL method
The suggested concentration for Trastuzumab biosimilar antibody for staining cells in flow cytometry is <= 0.25 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.